Crizotinib reduces tumor size in patients with ALK positive lung cancer
Thursday, September 6, 2012 - 14:30
in Health & Medicine
Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard of care for advanced stages of this disease, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.